Abstract
EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a role in lung cancers, with special emphasis on the way EGFR/Her-2 signaling cooperates with other signaling pathways.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Cell Transformation, Neoplastic*
-
Enzyme Inhibitors / therapeutic use
-
ErbB Receptors / physiology*
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / physiopathology*
-
Protein-Tyrosine Kinases / pharmacology
-
Receptor, ErbB-2 / physiology*
-
Signal Transduction*
Substances
-
Antibodies, Monoclonal
-
Enzyme Inhibitors
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2